Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 16/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20102599 | 0.94 | OPRL1 (0.35) | OPRL1FFAR4DGAT1 | |
| SCHEMBL20102541 | 0.83 | FFAR4 (0.34) | OPRL1FFAR4DGAT1 | |
| SCHEMBL20102608 | 0.82 | OPRL1 (0.35) | OPRL1FFAR4DGAT1 | |
| SCHEMBL20111477 | 0.81 | OPRL1 (0.36) | OPRL1CYP1A2 | |
| SCHEMBL20102581 | 0.81 | DGAT1 (0.36) | OPRL1FFAR4DGAT1 | |
| SCHEMBL20111592 | 0.81 | OPRL1 (0.35) | OPRL1CYP1A2 | |
| SCHEMBL20111329 | 0.80 | OPRL1 (0.40) | OPRL1 | |
| SCHEMBL20111265 | 0.78 | CAMKK1 (0.36) | FFAR4 | |
| SCHEMBL20111675 | 0.78 | OPRL1 (0.34) | OPRL1CYP1A2 | |
| SCHEMBL20117906 | 0.77 | MEN1 (0.31) | OPRL1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2019-06-18 | — | — | US | disclosed |
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX1, PIEZO1, C1S | OPRL1 1758/4885FFAR4 309/4885CYP1A2 436/4885 |
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | YBX1, PIEZO1, C1S | OPRL1 1758/4885FFAR4 309/4885CYP1A2 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.